Jazz Pharmaceuticals' FDA approval of a new indication for Xyrem gives narcolepsy patients age seven years old and older a treatment for cataplexy, or excessive daytime sleepiness,
Sun Pharma is introducing its Ilumya injectable, which has been approved by the Food and Drug Administration, for the treatment of moderate-to-severe plaque psoriasis in adults.
The FDA's approval of Regeneron and Sanofi's Dupixent provides patients with moderate-to-severe asthma, age 12 years old and older, with a new treatment option.